ZA202209632B - Molecules targeting mutant ras protein - Google Patents
Molecules targeting mutant ras proteinInfo
- Publication number
- ZA202209632B ZA202209632B ZA2022/09632A ZA202209632A ZA202209632B ZA 202209632 B ZA202209632 B ZA 202209632B ZA 2022/09632 A ZA2022/09632 A ZA 2022/09632A ZA 202209632 A ZA202209632 A ZA 202209632A ZA 202209632 B ZA202209632 B ZA 202209632B
- Authority
- ZA
- South Africa
- Prior art keywords
- ras protein
- mutant ras
- molecules targeting
- targeting mutant
- human ras
- Prior art date
Links
- 102000016914 ras Proteins Human genes 0.000 title abstract 3
- 108010014186 ras Proteins Proteins 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Aspects of the invention concern non-naturally occurring molecules configured to form an intermolecular beta-sheet with a human RAS protein mutated at position 12 or 13 and substantially not with wild-type human RAS protein, as well therapeutic applications thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20158306 | 2020-02-19 | ||
PCT/EP2021/054118 WO2021165452A1 (en) | 2020-02-19 | 2021-02-19 | Molecules targeting mutant ras protein |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA202209632B true ZA202209632B (en) | 2024-01-31 |
Family
ID=69726430
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2022/09632A ZA202209632B (en) | 2020-02-19 | 2022-08-29 | Molecules targeting mutant ras protein |
ZA2022/09674A ZA202209674B (en) | 2020-02-19 | 2022-08-30 | Molecules targeting ras protein |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2022/09674A ZA202209674B (en) | 2020-02-19 | 2022-08-30 | Molecules targeting ras protein |
Country Status (12)
Country | Link |
---|---|
US (2) | US20230100941A1 (en) |
EP (2) | EP4106787A1 (en) |
JP (2) | JP2023516137A (en) |
KR (2) | KR20220143702A (en) |
CN (2) | CN115916234A (en) |
AU (2) | AU2021223702A1 (en) |
BR (2) | BR112022016517A2 (en) |
CA (2) | CA3170658A1 (en) |
IL (2) | IL295634A (en) |
MX (2) | MX2022010191A (en) |
WO (2) | WO2021165452A1 (en) |
ZA (2) | ZA202209632B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
NO309798B1 (en) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition |
AU2006326940B2 (en) | 2005-12-22 | 2012-04-19 | Vib Vzw | Means and methods for mediating protein interference |
US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
AU2012228365A1 (en) | 2011-03-11 | 2013-09-19 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Molecules and methods for inhibition and detection of proteins |
WO2016154047A2 (en) * | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
US20180282397A1 (en) * | 2016-12-15 | 2018-10-04 | University Of Southern California | Polypeptides that bind activated ras proteins |
US11771749B2 (en) * | 2017-02-03 | 2023-10-03 | The Medical College Of Wisconsin, Inc. | KRAS peptide vaccine compositions and method of use |
MA50180A (en) * | 2017-09-20 | 2021-05-26 | Us Health | CLASS II HLA-RESTRICTED T-LYMPHOCYTE RECEPTORS AGAINST MUTÉ KRAS |
-
2021
- 2021-02-19 JP JP2022550695A patent/JP2023516137A/en active Pending
- 2021-02-19 CN CN202180028937.8A patent/CN115916234A/en active Pending
- 2021-02-19 US US17/800,738 patent/US20230100941A1/en active Pending
- 2021-02-19 MX MX2022010191A patent/MX2022010191A/en unknown
- 2021-02-19 WO PCT/EP2021/054118 patent/WO2021165452A1/en unknown
- 2021-02-19 EP EP21704699.4A patent/EP4106787A1/en active Pending
- 2021-02-19 IL IL295634A patent/IL295634A/en unknown
- 2021-02-19 CN CN202180028959.4A patent/CN115427057A/en active Pending
- 2021-02-19 BR BR112022016517A patent/BR112022016517A2/en not_active Application Discontinuation
- 2021-02-19 MX MX2022010193A patent/MX2022010193A/en unknown
- 2021-02-19 CA CA3170658A patent/CA3170658A1/en active Pending
- 2021-02-19 BR BR112022016513A patent/BR112022016513A2/en not_active Application Discontinuation
- 2021-02-19 AU AU2021223702A patent/AU2021223702A1/en active Pending
- 2021-02-19 KR KR1020227031655A patent/KR20220143702A/en unknown
- 2021-02-19 AU AU2021222972A patent/AU2021222972A1/en active Pending
- 2021-02-19 WO PCT/EP2021/054125 patent/WO2021165456A1/en unknown
- 2021-02-19 KR KR1020227031654A patent/KR20220143701A/en unknown
- 2021-02-19 JP JP2022550678A patent/JP2023514420A/en active Pending
- 2021-02-19 IL IL295623A patent/IL295623A/en unknown
- 2021-02-19 CA CA3171925A patent/CA3171925A1/en active Pending
- 2021-02-19 EP EP21704697.8A patent/EP4106785A1/en active Pending
- 2021-02-19 US US17/800,818 patent/US20230090247A1/en active Pending
-
2022
- 2022-08-29 ZA ZA2022/09632A patent/ZA202209632B/en unknown
- 2022-08-30 ZA ZA2022/09674A patent/ZA202209674B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL295623A (en) | 2022-10-01 |
BR112022016513A2 (en) | 2022-10-11 |
EP4106787A1 (en) | 2022-12-28 |
AU2021223702A1 (en) | 2022-08-25 |
ZA202209674B (en) | 2024-01-31 |
US20230100941A1 (en) | 2023-03-30 |
CN115427057A (en) | 2022-12-02 |
MX2022010193A (en) | 2022-11-14 |
JP2023514420A (en) | 2023-04-05 |
CN115916234A (en) | 2023-04-04 |
KR20220143701A (en) | 2022-10-25 |
CA3170658A1 (en) | 2021-08-26 |
BR112022016517A2 (en) | 2022-10-11 |
IL295634A (en) | 2022-10-01 |
EP4106785A1 (en) | 2022-12-28 |
WO2021165452A1 (en) | 2021-08-26 |
MX2022010191A (en) | 2022-11-14 |
KR20220143702A (en) | 2022-10-25 |
AU2021222972A1 (en) | 2022-08-25 |
US20230090247A1 (en) | 2023-03-23 |
CA3171925A1 (en) | 2021-08-26 |
WO2021165456A1 (en) | 2021-08-26 |
JP2023516137A (en) | 2023-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551261A1 (en) | Il-15 conjugates and uses thereof | |
EP4295846A3 (en) | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
MX2021013661A (en) | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof. | |
WO2017134302A3 (en) | Targeted therapeutic agents and uses thereof | |
PH12019502149A1 (en) | Optimized antibody compositions for treatment of ocular disorders | |
MA49339A (en) | Oligomer extended insulin-fc conjugates | |
ZA202209632B (en) | Molecules targeting mutant ras protein | |
ATE452908T1 (en) | IL-10 MUTANT | |
MX2021014473A (en) | Compounds and methods targeting human tau. | |
MX2019002019A (en) | Beta-amino-isoquinolinyl amide compounds. | |
MX2023001292A (en) | Conjugated hepcidin mimetics. | |
EA202191175A1 (en) | CYSTEINE-DESIGNED ANTIBODY-DRUG CONJUGATES CONTAINING PEPTIDE-CONTAINING LINKERS | |
EA202191280A1 (en) | DELIVERY CONSTRUCTS FOR TRANSCYTOSIS AND RELATED METHODS | |
MD3768284T2 (en) | Compositions of entrecoccus flagellin for use in therapy | |
MX2021012047A (en) | Serpin fusion polypeptides and methods of use thereof. | |
MA45172B1 (en) | MODIFIED RNA ENCODING VEGF-A POLYPEPTIDES, FORMULATIONS AND USES THEREOF | |
EA202192625A1 (en) | PSEUDOKINASE TYK2 LIGANDS | |
MX2021009555A (en) | Tyk2 pseudokinase ligands. | |
MX2019012347A (en) | Optimization of enzyme replacement therapy for treatment of homocystinuria. | |
PH12021550789A1 (en) | Disulfide bond stabilized polypeptide compositions and methods of use | |
MY193353A (en) | Anti-vegf protein compositions and methods for producing the same | |
MX2020007555A (en) | Factor h potentiating antibodies and uses thereof. | |
MX2021015333A (en) | Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer. | |
CY1121886T1 (en) | PHENYLALANINE-FREE PROTEIN FOR THE TREATMENT OF PKU | |
MX2021005910A (en) | High concentration protein formulation. |